PreveCeutical Medical Inc. (PRVCF) Stock

About PreveCeutical Medical Inc.

Vancouver, Canada-based PreveCeutical Medical Inc. operates as a health sciences company, focusing on the creation of both preventative and curative treatments derived from organic and nature-identical substances. The company's innovative pipeline includes a cannabinoid Sol-Gel Delivery system designed for nose-to-brain administration, offering potential relief for ailments such as pain, inflammation, seizures, and various neurological disorders. Other key initiatives involve the BSV Peptide Program, aimed at halting cancer progression; a non-addictive analgesic for effective pain management; and a Dual Gene Therapy addressing type 2 diabetes and obesity. Furthermore, PreveCeutical is developing a diverse array of medicinal products based on cannabis.

PreveCeutical Medical Inc. is headquartered in CA.

PreveCeutical Medical Inc. (PRVCF) stock trades at $0.01 with a market capitalization of $8.37M. The stock is valued at a price-to-earnings (P/E) ratio of -5.00, price-to-book of -1.44, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.04, and currently trades 75.0% below its 52-week high.

On profitability, PreveCeutical Medical Inc. generates a return on equity (ROE) of 23.09% — well above the market average, a sign of a high-quality business, return on capital employed of 59.39%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.preveceutical.com